Astellas Pharma Inc.
4503.T
Below: live stock price for Astellas Pharma Inc. (4503.T), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Astellas Pharma Inc. (4503.T) is a Healthcare company based in Japan. Operating in Drug Manufacturers - General, it employs about 14,099 people. Over the past year 4503.T traded between 1,637 and 2,717 JPY. Trailing P/E sits near 12.66 on a market cap of about 4.61T JPY. It currently yields 3.11% in dividends.
- Prev close
- $15.96
- Volume (24h)
- $107.14M
- Market cap
- $29.27B
- Currency
- USD (native JPY)
Score
65/ 100 · Solid
- Value84
- Quality71
- Momentum67
- Growth84
- Risk62
- Dividend61
- Liquidity26
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 16.3895 +0.40%
- +20 bars
- 16.4797 +0.95%
- +60 bars
- 16.5147 +1.17%
- +120 bars
- 16.516 +1.17%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.75% per bar.
Interpretation
Composite signals look solid. Strength: valuation with weakness: balance-sheet liquidity. Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value84/100
Value looks strong — driven by P/E (12.66).
P/E:12.66P/B:2.37PEG:0.37 - Quality71/100
Quality looks solid — driven by Gross margin (80.82%).
ROE:21.30%ROA:8.41%Profit margin:16.05%Gross margin:80.82% - Momentum67/100
Momentum looks solid — driven by 52w change (50.92%).
52w change:50.92% - Growth84/100
Growth looks strong — driven by Earnings growth (107.20%).
Revenue growth:26.70%Earnings growth:107.20% - Risk62/100
Risk looks solid — driven by Debt / equity (30.34).
Beta:0.09Debt / equity:30.34 - Dividend61/100
Dividend looks solid — driven by Payout ratio (38.41%).
Dividend yield:3.11%Payout ratio:38.41% - Liquidity26/100
Liquidity looks fragile — driven by Current ratio (1.2).
Current ratio:1.2Quick ratio:0.88
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 241 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 29.8%
- Max drawdown
- -20.7%
- Below period high
- -5.4%
- Best day
- +7.72%
- Worst day
- -4.77%
- Up days
- 52%
- Current streak
- 2 up
- Typical day swing
- 2.2%
- Volume vs average
- -7%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 16.4704 high → 13.4925 low · 60 bars
- ResistanceFib +161.8% extensionnot reached21.2886 USD+30.41% from current
- ResistanceFib +100% extensionnot reached19.4483 USD+19.14% from current
- ResistanceFib +61.8% extensionnot reached18.3108 USD+12.17% from current
- ResistanceFib +27.2% extensionnot reached17.2804 USD+5.86% from current
- Current16.3244 USD
- SupportFib 23.6% retracementNearesttested 2×15.7676 USD-3.41% from current
- SupportFib 38.2% retracementtested 10×15.3329 USD-6.07% from current
- SupportFib 50% midpointtested 11×14.9815 USD-8.23% from current
- SupportFib 61.8% retracementtested 14×14.6301 USD-10.38% from current
- SupportFib 78.6% retracementtested 5×14.1298 USD-13.44% from current
- SupportFib −27.2% extensionnot reached12.6826 USD-22.31% from current
- SupportFib −61.8% extensionnot reached11.6522 USD-28.62% from current
- SupportFib −100% extensionnot reached10.5147 USD-35.59% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- ¥2,717
- 52w low
- ¥1,637
- 52w change
- 50.92%
- Day high
- ¥2,594
- Day low
- ¥2,513.5
- P/E (TTM)
- 12.66
- Forward P/E
- 33.93
- PEG
- 0.37
- Price / Book
- 2.37
- Beta (5Y)
- 0.09
- Enterprise value
- 4.96T
- EV / Revenue
- 2.18
- EV / EBITDA
- 7.4
- EPS (TTM)
- ¥203.07
- Forward EPS
- ¥75.77
- Dividend yield
- 3.11%
- Dividend rate
- ¥80
- Payout ratio
- 38.41%
- Revenue (TTM)
- 2.27T
- EBITDA
- 669.55B
- Free cash flow
- 383.56B
- Total cash
- 244.7B
- Total debt
- 589.87B
- Debt / Equity
- 30.34
- Current ratio
- 1.2
- Quick ratio
- 0.88
- Profit margin
- 16.05%
- Gross margin
- 80.82%
- Return on assets
- 8.41%
- Return on equity
- 21.30%
- Shares outstanding
- 1.79B
- Float
- 1.79B
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.09
- very stable
- 52-week change
- 50.92%
- Debt / Equity
- 30.34
- very high leverage
- Current ratio
- 1.2
- Quick ratio
- 0.88
- ROE
- 21.30%
- ROA
- 8.41%
- PEG ratio
- 0.37
- EV / Revenue
- 2.18
- EV / EBITDA
- 7.4
- Revenue growth
- 26.70%
- Earnings growth
- 107.20%
- EBITDA
- 669.55B
- Free cash flow
- 383.56B
- Total cash
- 244.7B
- Total debt
- 589.87B
- Insider holdings
- 0.08%
- Institutional
- 62.30%
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.